Mary Chapman, features writer —

After a two-year hiatus, the Muscular Dystrophy Association (MDA) is bringing back its in-person Wings Over Wall Street fundraiser gala in New York City, with proceeds going to support MDA research into promising amyotrophic lateral sclerosis (ALS) treatments. The June 9 event, starting at 6 p.m. EST at…

After several years of support, the late-stage biopharmaceutical company Cytokinetics is reaffirming its commitment to the ALS Association and its efforts to battle amyotrophic lateral sclerosis (ALS) and assist the ALS community. In addition to backing nationwide organizational efforts, Cytokinetics has, for more than a decade, provided support…

Silence ALS, a new initiative supported by Target ALS, set as its goals discovering and developing personalized antisense oligonucleotide (ASO) treatments for amyotrophic lateral sclerosis (ALS) patients with rare disease-causing mutations, while advancing understanding of the disease’s overall biology. The initiative, a collaboration between the n-Lorem Foundation, which…

The ALS Association is calling for applications for a new Seed Grant Program designed to support exploratory amyotrophic lateral sclerosis (ALS) research. The one-year grants of up to $50,000 each will fund investigations that could have a significant impact on the progressive neurodegenerative disorder. Specifically, funded projects…

The Canadian province of British Columbia is giving another CA$2 million (about $1.65 million) to help establish “Project Hope” — what organizers hope will be a world-class amyotrophic lateral sclerosis (ALS) center at the University of British Columbia (UBC). With the new funding, to the ALS Society…

A two-year project aims to identify reliable blood tests for measuring neurofilament protein levels, which could aid in the early detection of frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS), and possibly other rare neurodegenerative disorders. Neurofilament, a protein component of neurons, is released when these nerve cells are…

Minnesota lawmaker Dave Lislegard has introduced two measures in the state’s legislature that would invest tens of millions of dollars in amyotrophic lateral sclerosis (ALS) research and caregiver support. The first bill, HF 3603, would appropriate $20 million to the University of Minnesota for competitive research grants to…

In response to the National Institute of Neurological Disorders and Stroke‘s (NINDS) request for community input regarding what it should prioritize to accelerate amyotrophic lateral sclerosis (ALS) research, the ALS Association’s overarching message is this: move swiftly to help patients. NINDS, which is part of the National…

The ALS Canada Research Program and the Brain Canada Foundation partnered to award CA$1.125 million (about $885,600) in grants to advance the understanding, diagnosis, and treatment of amyotrophic lateral sclerosis (ALS). The nine multidisciplinary research grants, awarded late last year to teams across Canada, seek to promote global…

The Canadian Neuromuscular Disease Registry (CNDR) and Amylyx Pharmaceuticals are collaborating on an initiative that could produce the first real-world evidence on AMX0035, Amylyx’s investigational therapy to slow functional decline in amyotrophic lateral sclerosis (ALS) patients. The two, in partnership with neuromuscular centers across Canada, will collect…